socalTECH

JANUARY 3, 2019

Thousand Oaks- and Shanghai-based Thousand Oaks Biopharmaceuticals , a new contract manufacturing organization fort he biotech industry, said it has received $45M in a Series A financing round. The company's Chairman is Shun Luo, Ph.D.,

Thousand Oaks 100

Thousand Oaks Outsource Development Media Organization 100

socalTECH

APRIL 29, 2021

Thousand Oaks-based Capsida Biotherapeutics, a new biotechnology company focused on using adeno-associated virus (AAV) engineering and cargo development platform to develop tissue-targeted gene therapies for multiple types of diseases, has uncloaked from stealth mode, saying it has raised $140M in total capital.

Westlake Village 113

Westlake Village Thousand Oaks Funding CalTech 113

socalTECH

NOVEMBER 17, 2017

Amgen Ventures , the venture investment arm of Thousand Oaks-based Amgen , is one of the new investors in precision oncology and medicine startup Syapse. READ MORE>>.

Thousand Oaks 113

Thousand Oaks Funding Software Capital 113

socalTECH

MARCH 8, 2016

Thousand Oaks-based Amgen has made another investment this morning in immunology startup Tizona Therapeutics , via its venture capital arm, Amgen Ventures. Series A investors--including Amgen Ventures--also participated, with investments from MPM Capital, Astellas Venture Management and InterWest Partners.

Thousand Oaks 100

Thousand Oaks Funding Venture Capital Invest 100

socalTECH

DECEMBER 17, 2013

Thousand Oaks-based biopharmaceuticals startup Atara Biotherapeutics announced this morning that it has raised $38.5M in a Series B funding round, for its efforts to develop treatments for patients with end-stage renal disease. atara biotherapeutics venture capital renal disease lifescience amgen' READ MORE>>.

Thousand Oaks 180

Thousand Oaks Venture Capital Capital Funding 180

socalTECH

OCTOBER 12, 2016

Thousand Oaks-based Akriveia Therapeutics , a biotechnology startup focused on immuno-oncology, announced this morning that it has raised $7.5M The investment came from F-Prime Capital Partners. in a Series A investment.

Thousand Oaks 100

Thousand Oaks Research Activity Invest 100

socalTECH

NOVEMBER 7, 2013

Thousand Oaks-based ImmunGene , a startup biotech company developing antibody-based, protein therapeutics for treating cancer, said today that it has raised $9M in a Series A funding, to advance its early stage development products. The startup is led by Sanjay D. to its board of directors. READ MORE>>.

Thousand Oaks 164

Thousand Oaks UCLA Venture Capital Equity 164